Repligen Corporation $RGEN Stock: Jefferies Financial Group Inc. Reduces Stake

Jefferies Financial Group Inc. cut its holdings in Repligen Corporation (NASDAQ:RGEN) by 99.9% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 5,503 shares of the biotechnology company’s stock after selling 5,659,497 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Repligen were worth $1,058,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RGEN. United Capital Financial Advisors LLC acquired a new position in Repligen during the second quarter worth about $380,756,000. Wasatch Advisors LP lifted its holdings in shares of Repligen by 27.9% in the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after acquiring an additional 346,720 shares during the last quarter. Maverick Capital Ltd. bought a new position in shares of Repligen in the first quarter worth about $178,946,000. Congress Asset Management Co. lifted its holdings in shares of Repligen by 0.9% in the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company’s stock worth $196,249,000 after acquiring an additional 8,681 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Repligen by 6.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 854,741 shares of the biotechnology company’s stock valued at $100,681,000 after purchasing an additional 50,331 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 0.8%

NASDAQ RGEN traded up $1.27 on Friday, reaching $167.79. The company had a trading volume of 510,110 shares, compared to its average volume of 1,292,036. The firm has a market cap of $10.73 billion, a price-to-earnings ratio of -798.96, a P/E/G ratio of 2.85 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.88 and a quick ratio of 8.43. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $198.87. The business has a 50 day moving average of $177.15 and a two-hundred day moving average of $145.67.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.46 by $0.07. The firm had revenue of $209.31 million for the quarter, compared to the consensus estimate of $206.70 million. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.46 EPS. Analysts forecast that Repligen Corporation will post 2.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on RGEN shares. UBS Group restated a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Zacks Research cut shares of Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Wells Fargo & Company increased their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. upped their target price on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, Royal Bank Of Canada increased their target price on Repligen from $185.00 to $200.00 and gave the company an “outperform” rating in a research report on Wednesday, October 28th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $178.57.

Repligen Company Profile

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.